TCIM
OMED

TIAA CREF Investment Management’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

TIAA CREF Investment Management’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-51,311
Closed -$473K – 3272
2017
Q1 		$473K Sell
51,311
-7,018
-12% -$61.6K ﹤0.01% 2807
2016
Q4 		$450K Buy
58,329
+1,043
+2% +$9.58K ﹤0.01% 2883
2016
Q3 		$655 Buy
57,286
+1,389
+2% +$16.2K ﹤0.01% 2744
2016
Q2 		$688K Buy
55,897
+2,294
+4% +$27.8K ﹤0.01% 2716
2016
Q1 		$542K Sell
53,603
-36,836
-41% -$432K ﹤0.01% 2765
2015
Q4 		$2.04M Hold
90,439
– – ﹤0.01% 2138
2015
Q3 		$1.5M Sell
90,439
-2,008
-2% -$40.3K ﹤0.01% 2320
2015
Q2 		$2.08M Buy
92,447
+12,506
+16% +$308K ﹤0.01% 2278
2015
Q1 		$2.06M Buy
79,941
+7,240
+10% +$184K ﹤0.01% 2201
2014
Q4 		$1.58M Buy
72,701
+7,473
+11% +$153K ﹤0.01% 2393
2014
Q3 		$1.24M Sell
65,228
-7,033
-10% -$141K ﹤0.01% 2518
2014
Q2 		$1.68M Buy
72,261
+59,581
+470% +$1.47M ﹤0.01% 2408
2014
Q1 		$427K Hold
12,680
– – ﹤0.01% 2985
2013
Q4 		$374K Buy
12,680
+2,600
+26% +$47.6K ﹤0.01% 3019
2013
Q3 		$154K Buy
+10,080
New +$187K ﹤0.01% 3068

Other funds holding OMED

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
IHM
Iguana Healthcare Management New York $152M AUM 48.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TIAA CREF Investment Management's OMED Position: Q2 2017 in Review

TIAA CREF Investment Management sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q2 2017, closing a stake of 51,311 shares — an estimated $473K sold.

TIAA CREF Investment Management first reported a position in OMED in Q3 2013 and held it in 15 quarters. The position peaked at $2.08M in Q2 2015. 68 funds tracked by Wall St. Rank hold OMED as of Q2 2017.

  • TIAA CREF Investment Management reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
  • TIAA CREF Investment Management sold 51,311 OncoMed Pharmaceuticals, Inc. shares in Q2 2017, an estimated $473K.
  • TIAA CREF Investment Management first reported a position in OncoMed Pharmaceuticals, Inc. in Q3 2013 and held it in 15 quarters.
  • TIAA CREF Investment Management's OncoMed Pharmaceuticals, Inc. position peaked at $2.08M in Q2 2015.
  • 68 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q2 2017.

Based on TIAA CREF Investment Management's 13F filing for Q2 2017, filed 10 Aug 2017.